VIIV HEALTHCARE CO. V. GILEAD SCIENCES CANADA, INC.,

JurisdictionFederal Jurisdiction (Canada)
Neutral Citation2021 FCA 122
Citation2021 FCA 122
CourtCourt of Appeal (Canada)
Date16 June 2021
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
12 practice notes
  • Canada v. Witchekan Lake First Nation, 2023 FCA 105
    • Canada
    • Court of Appeal (Canada)
    • May 17, 2023
    ...215 must be interpreted and applied consistently with the objectives in Rule 3 (ViiV Healthcare Company v. Gilead Sciences Canada, Inc., 2021 FCA 122, 460 D.L.R. (4th) 272 at para. 37 [ViiV Healthcare]). Rule 3 seeks to “secure the just, most expeditious and least expensive outcome o......
  • Greenblue Urban North America Inc. v. Deeproot Green Infrastructure, LLC, 2023 FCA 184
    • Canada
    • Court of Appeal (Canada)
    • September 13, 2023
    ...Inc. v. Pharmascience Inc., 2022 FCA 143, 196 C.P.R. (4th) 120 at para. 38; Viiv Healthcare Company v. Gilead Sciences Canada, Inc., 2021 FCA 122, 460 D.L.R. (4th) 272 at para. 56; Evolution Technologies Inc. v. Human Care Canada Inc., 2019 FCA 209, 167 C.P.R. (4th) 285 at para. 17; ABB Tec......
  • Alberta v. Canadian Copyright Licensing Agency, 2024 FC 292
    • Canada
    • Federal Court (Canada)
    • February 22, 2024
    ...just, most expeditious and least expensive’ way’” [see ViiV Healthcare Company v. Gilead Sciences Canada, Inc, 2021 FCA 122 at paras [146] The rules applicable to summary trials are found in Part 4 of the Rules. Rule 213(1) allows a party to bring a motion for summary t......
  • Deeproot Green Infrastructure, LLC v. Greenblue Urban North America Inc., 2023 FCA 185
    • Canada
    • Court of Appeal (Canada)
    • September 13, 2023
    ...or substituted with something else: ViiV Healthcare Company v. Gilead Sciences Canada, Inc., 2020 FC 486 at para. 175, aff’d 2021 FCA 122, leave to appeal denied [2021] S.C.C.A. No. 306. This is so even if the allegedly infringing device performs substantially the same function as th......
  • Request a trial to view additional results
11 cases
  • Canada v. Witchekan Lake First Nation, 2023 FCA 105
    • Canada
    • Court of Appeal (Canada)
    • May 17, 2023
    ...215 must be interpreted and applied consistently with the objectives in Rule 3 (ViiV Healthcare Company v. Gilead Sciences Canada, Inc., 2021 FCA 122, 460 D.L.R. (4th) 272 at para. 37 [ViiV Healthcare]). Rule 3 seeks to “secure the just, most expeditious and least expensive outcome o......
  • Greenblue Urban North America Inc. v. Deeproot Green Infrastructure, LLC, 2023 FCA 184
    • Canada
    • Court of Appeal (Canada)
    • September 13, 2023
    ...Inc. v. Pharmascience Inc., 2022 FCA 143, 196 C.P.R. (4th) 120 at para. 38; Viiv Healthcare Company v. Gilead Sciences Canada, Inc., 2021 FCA 122, 460 D.L.R. (4th) 272 at para. 56; Evolution Technologies Inc. v. Human Care Canada Inc., 2019 FCA 209, 167 C.P.R. (4th) 285 at para. 17; ABB Tec......
  • Alberta v. Canadian Copyright Licensing Agency, 2024 FC 292
    • Canada
    • Federal Court (Canada)
    • February 22, 2024
    ...just, most expeditious and least expensive’ way’” [see ViiV Healthcare Company v. Gilead Sciences Canada, Inc, 2021 FCA 122 at paras [146] The rules applicable to summary trials are found in Part 4 of the Rules. Rule 213(1) allows a party to bring a motion for summary t......
  • Deeproot Green Infrastructure, LLC v. Greenblue Urban North America Inc., 2023 FCA 185
    • Canada
    • Court of Appeal (Canada)
    • September 13, 2023
    ...or substituted with something else: ViiV Healthcare Company v. Gilead Sciences Canada, Inc., 2020 FC 486 at para. 175, aff’d 2021 FCA 122, leave to appeal denied [2021] S.C.C.A. No. 306. This is so even if the allegedly infringing device performs substantially the same function as th......
  • Request a trial to view additional results
2 firm's commentaries

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT